Natarajan and coworkers (2012) observed that prostate cancer cell line 22RV1 is resistant to paclitaxel, methotrexate, and doxorubicin due to high BCRP and ABCG2 expression levels [58]. This evidence concerns the gene ABCG2 and prostate carcinoma.